hCG Treatment for Rehabilitation From a TBI (NCT07557615) | Clinical Trial Compass
Not Yet RecruitingEarly Phase 1
hCG Treatment for Rehabilitation From a TBI
United States50 participantsStarted 2026-10-01
Plain-language summary
The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.
Who can participate
Age range18 Years – 65 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male subjects aged 18-65
* Subject is 1-month but \< 6-month post-TBI with a msTBI defined as Glasgow Coma Scale (GCS) 4-12 (inclusive) at the time of the TBI, and/or at the time of screening (Visit 1)
* Stable doses of any medication, supplement or medical food that may affect brain function, unless deemed medically necessary by the patient's physician for optimal healthcare
* Fluent in English
* Reasonable expectation of availability to receive the 24-week course of therapy and be available for follow up evaluations
Exclusion Criteria:
* Significantly depressed (Geriatric Depression Scale \> 10)
* Patients considered to be at risk for suicidality or homicidality according to the Columbia Suicide Severity Rating Scale (CSSRS)
* Primary hypogonadism (unrelated to trauma)
* Renal disease; Asthma; known endocrine or germ cell tumor
* Taking other medications known to affect serum sex hormone or gonadotropin concentrations such as testosterone for hormone replacement therapy, goserelin or danazol, in the past three (3) months
* Presence of significant systemic illness likely to interfere with participation in or completion of the study or to affect study results
* Receiving other investigational drugs within 30 d or 5 half-lives prior to randomization, whichever longer
* Male patients with known/documented elevated PSA levels, or a PSA level of 4ng/mL at screening
* History of deep venous thrombosis (DVT) or venous thromboembolism (VTE)
* Clinically sign…
What they're measuring
1
Percent change in Treatment-Emergent Adverse Events